Virtual consulting · Worldwide
NeuciteConsultingRequest a quote

Competitive intelligence read by scientists, not just collected

Technology landscapes by mechanism, rival program tracking and a monthly digest in which a scientist has checked every item against its source. Public sources only, so your team acts on what matters.

Information is easy to gather and hard to read

Most life sciences teams already receive more alerts than they can read. The gap is not access to data. It is knowing which trial, paper or patent filing changes your position. Our competitive intelligence work closes that gap. We combine structured collection from public sources with interpretation by scientists who understand the mechanisms, materials and endpoints involved.

A technology landscape analysis maps a field by how products work, not only by who makes them. Grouping approaches by mechanism shows where effort is crowded, where evidence is weak and where white space may exist. That view supports portfolio choices, partnering talks and target product profiles. It also helps explain your differentiation to investors and partners.

Ongoing work covers pipeline tracking and literature monitoring. We follow company disclosures, clinical trial registries, conference abstracts, regulatory databases and the peer-reviewed literature. AI tools may be used to pre-sort large volumes of records; they do not decide what is reported. A scientist reads every item and checks it against its source before it reaches you, and each one carries its source so you can verify it.

We work only with public and lawfully available information. We do not pose as customers, and we do not seek confidential data from competitors' staff. Patent items are screened for technical relevance only. Anything that may raise a legal question goes to your patent counsel, who decides what it means for your freedom to operate.

What competitive intelligence work delivers

One-off landscapes answer a strategic question. Monitoring keeps the answer current.

01

Technology landscape report

A structured map of approaches in your field, grouped by mechanism or technology, with the leading programs, evidence strength and development stage for each group.

02

White space analysis

An assessment of where needs remain unmet, where evidence is thin, and where technical barriers have kept others out, framed as options for your R&D team.

03

Competitor program profiles

Profiles of rival programs drawn from pipelines, trial registries, publications and regulatory records. Each covers indication, design, endpoints, expected timelines and recent changes to the program.

04

Monthly monitoring digest

A scientist-checked summary of new papers, trial registrations, regulatory events and patent alerts in your area, ranked by relevance and linked to the original source.

05

Patent alert screening

Technical screening of newly published patent applications and grants against your areas of interest. Items that may matter are flagged, with a short note, for your patent counsel to assess.

06

Briefing sessions

We share draft findings for your comments and answer questions in writing. Your feedback helps us refine which topics to monitor.

How we set up and run competitive intelligence work

Define the questions

We agree the decisions the intelligence must support, the competitors and technologies in scope, and the sources to use. Clear questions keep reports short and stop monitoring from turning into noise.

Collect and verify

We build searches across literature, registries, regulatory and patent databases. AI-assisted screening narrows the volume. Scientists then review each item, check it against the source, and remove duplicates and false positives.

Interpret and update

We explain what each finding means for your program and rate its relevance. For monitoring, searches run on a fixed schedule and the scope is reviewed with you at agreed intervals.

How intelligence questions typically arrive

A

Medical device developer

Where is there room in antimicrobial catheter coatings?

Situation
A developer is weighing a new antimicrobial coating for urinary or vascular catheters. The field looks crowded, and claims vary widely. Leadership wants to know which approaches have real clinical evidence and whether any technical white space remains.
How we advise
We would map coatings by mechanism: silver-based release, chlorhexidine and other antiseptics, nitric oxide-releasing polymers, and zwitterionic antifouling surfaces. For each group we would review clinical and preclinical evidence, durability, resistance concerns and regulatory history. We would then compare the groups on unmet needs, such as long-term efficacy or fewer resistance concerns.
What you receive
A technology landscape report organized by mechanism, an evidence summary per group, and a white space analysis framed as options for the R&D team.
B

Clinical-stage biotech

Keeping track of rival programs without a dedicated team

Situation
A small biotech has three competitors in the same indication. Updates arrive through investor decks, registry changes and conference posters. Nobody has time to follow them all, and the board keeps asking what rivals are doing.
How we advise
We would set up pipeline tracking for each rival program. That covers trial registries, company disclosures, publications and conference abstracts. Changes in enrollment targets, endpoints or status would be flagged with a note on what they may mean. A quarterly summary would put the changes in context for board discussion.
What you receive
Competitor program profiles, a change log with sources, and a quarterly board-ready summary of what moved and why it may matter.
C

R&D team in a mid-size company

Too many alerts and no time to read them

Situation
Scientists receive dozens of database alerts every week. Most are irrelevant, and the important ones get missed or read too late. The team wants one reliable digest that someone has actually read, checked against the source and ranked.
How we advise
We would agree the topics, sources and relevance criteria with the team. AI-assisted pre-sorting would reduce the volume each month. A scientist would review every candidate item, remove false positives and write a short note on why each kept item matters. The scope would be reviewed with the team each quarter.
What you receive
A monthly literature monitoring digest, ranked by relevance, with source links and short notes, plus an archive of past digests.

Illustrative scenarios. Each is a composite of common client situations, not a specific engagement.

Frequently asked questions

What sources do you use?

We use public and lawfully accessible sources: bibliographic databases, clinical trial registries, regulatory databases, company disclosures, conference abstracts and public patent databases. Commercial patent databases are used only on request, and their cost is billed to you. Every item we report is linked to its source so your team can check it.

How do you use AI, and how is accuracy checked?

AI tools help us screen and summarize large volumes of records. They can miss items or misstate findings, so they do not make the final call. A scientist reviews every item before it reaches you and checks the summary against the source. The search method is documented, so coverage can be reviewed.

Is this an alternative to a freedom-to-operate opinion?

No. Our patent alerts and landscapes are technical analyses of what has been filed or published. They do not assess validity, infringement or claim scope in a legal sense. When an item may affect your plans, we flag it for your patent counsel, who can give a legal opinion.

How long does a landscape take?

It depends on how broad the field is and how many programs are in scope. A focused landscape on one technology class may take a few weeks. A broad landscape across several mechanisms and indications takes longer. We confirm the timeline in the written quote.

What do you need from us to start?

We need the decisions the work should support, the competitors or technologies you already track, and any terms or sources you know matter. A short internal briefing helps us avoid reporting what you already know. For monitoring, we also need one contact who can tell us when the scope should change.

Can monitoring start small and grow?

Yes. Many teams start with one topic or a few competitors, then add areas once the digest proves useful. Scope is reviewed at agreed intervals, usually each quarter. Changes to topics or sources are agreed in writing, so the search method stays documented and comparable over time.

Tell us what you need to watch

Tell us your field, what you already track, and the decision ahead. We’ll recommend a landscape review, ongoing monitoring, or both and send a written quote.

Neucite Consulting uses public and lawfully available sources only; patent findings are technical analysis for your patent counsel, not legal opinions on validity, infringement or freedom to operate.